|
1 pahu (10 Vials)
| Ka nui: | |
|---|---|
▎ Kūlana Tirzepatid
Puna: PubChem |
Kaʻina: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamm a-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Hui Molekala: C 225H 348N 48O68 Kaumaha Molekala: 4813 g/mol Helu CAS: 2023788-19-2 PubChem CID: 163285897 Synonyms: Zepbound; Mounjaro |
▎ ʻImi ʻo Tirzepatid
He aha ke kumu noiʻi o Tirzepatid?
ʻO ke kumu o ka noiʻi ʻana o Tirzepatid ma muli o ka ʻimi ʻana i nā lāʻau lapaʻau maʻi diabetes a me ke koi no nā lāʻau hoʻokele kaumaha. He mau palena nā lāʻau lapaʻau kuʻuna maʻi diabetes, ʻoiai ʻo GLP-1 receptor agonists e hōʻike ana i ka pono nui i ka hoʻomaikaʻi ʻana i ke kahe koko koko, e koi ana i nā mea noiʻi e hoʻomohala i nā lāʻau lapaʻau ʻoi aku ka maikaʻi o ka papa like. Ma ke ʻano he GIP/GLP-1 ʻelua receptor agonist, hiki iā Tirzepatid ke hoʻoponopono maikaʻi i nā pae glucose koko. ʻO ka piʻi ʻana o ke ao holoʻokoʻa i ka nui o ka nui a me ka nui o ka heluna kanaka i hana i ka mālama paona i mea e koi koke ai. Loaʻa i ka GLP-1 receptor agonists nā hopena hoʻohaʻahaʻa kaumaha, e hoʻolilo iā lākou i pahuhopu no ka pohō kaumaha. Ua loaʻa ka manaʻo o Tirzepatid ma muli o kāna mau hopena maikaʻi i ke kaumaha.
He aha ke ʻano o ka hana a Tirzepatid?
ʻO ka hana agonist receptor pālua:
ʻO Tirzepatid kahi ʻelua glucagon-like peptide-1 (GLP-1) a me ka glucose-dependent insulinotropic polypeptide (GIP) receptor agonist [1,2] (Wong E, 2023; Kumar D, 2022). ʻO GLP-1 a me GIP nā hormones incretin i hana ʻia i loko o ka ʻōpū, e pāʻani ana i kahi kuleana koʻikoʻi i ka mālama ʻana i ka homeostasis glucose. Hoʻohana ʻo Tirzepatid i kahi hopena synergistic ma ka hoʻoulu ʻana i ka GLP-1 a me GIP receptors, a laila e hoʻoponopono i nā pae glucose koko.
Hoʻoponopono i ka insulin a me ka huna ʻana o ka glucagon:
Hoʻonui ia i ka synthesis a me ka huna ʻana o ka insulin i ka wā e hōʻemi ana i ka hoʻokuʻu ʻana o ka glucagon ma ke ʻano pili glucose. Ke piʻi ke kiʻekiʻe o ka glucose i ke koko, hoʻoulu ʻo Tirzepatid i nā pancreatic β-cells e hūnā i ka insulin, e hoʻoikaika ana i ka lawe ʻana a me ka hoʻohana ʻana i ka glucose, a laila e hoʻohaʻahaʻa i nā pae glucose koko; I ka manawa like, ke kāohi nei ia i nā pancreatic α-cells mai ka huna ʻana i ka glucagon, e hōʻemi ana i ka hoʻopuka ʻana o ka glucose hepatic, e hoʻohaʻahaʻa hou i ke kiʻekiʻe o ka glucose koko, a me ka hoʻomalu pono ʻana i ka hoʻokē ʻai a me ka postprandial blood glucose pae [1,3].
Nā ʻano hana ʻē aʻe:
Hoʻoikaika pū ʻo Tirzepatid i ka satiety, e pili ana paha i ka hoʻoulu ʻana i nā mea hoʻokipa GLP-1, e hana ana i ka ʻōnaehana o ke kikowaena, a me ka hoʻoulu ʻana i nā kikowaena hoʻoponopono makemake, e alakaʻi ana i nā mea maʻi e hōʻemi i ka ʻai ʻana i ka meaʻai a ma laila e kōkua ai i ka pohō kaumaha. Hoʻopaneʻe hoʻi ia i ka hoʻokuʻu ʻana o ka ʻōpū, hoʻolōʻihi i ka manawa e waiho ai ka meaʻai i loko o ka ʻōpū a komo mālie i loko o ka ʻōpū liʻiliʻi, a laila e pale ai i ka piʻi wikiwiki ʻana o ke kiʻekiʻe o ka glucose koko [1].
Kiʻi 1 Mechanism o ka hana o T irzepatide [6].
He aha nā mea hoʻohana o T irzepatide?
Ka mālama ʻana i ka maʻi diabetes type 2:
Ua ʻae ʻia ʻo Tirzepatid no ka mālama ʻana i nā poʻe maʻi me ka maʻi diabetes type 2 ma ke ʻano he mea hoʻohui i ka meaʻai a me ka hoʻoikaika kino. Ua hōʻike ʻia ka hoʻāʻo SURPASS ua hoʻemi nui ʻo Tirzepatid i ka pae hemoglobin A1c (HbA1c), me ka hoʻemi ʻana mai -1.87% a -2.59% (-20 a -28 mmol/mol). Hōʻike pū ia i ka mana glycemic kiʻekiʻe i hoʻohālikelike ʻia i kekahi mau agonists receptor GLP-1, e like me semaglutide 1 mg i ka hoʻāʻo SUPRASS-2. Eia hou, hiki iā ia ke hoʻemi i ke kaumaha o ke kino, me ka pohō kaumaha mai -6.2 a -12.9 kg i nā haʻawina hauʻoli, he mea koʻikoʻi loa ia no nā poʻe maʻi me ka maʻi maʻi type 2 i loaʻa pinepine i nā pilikia kaumaha a i ʻole ka momona [1,4].
Ka mālama ʻana i ka momona:
No ka mea, hoʻolaha ʻo Tirzepatid i ka māʻona, hoʻemi i ka ʻai ʻana i ka meaʻai, a hoʻoikaika i ka pohō kaumaha, loaʻa iā ia ka waiwai therapeutic no nā maʻi me ka momona. Hōʻike nā haʻawina e hiki ke hoʻemi i ke kaumaha ma luna o 20%, hoʻomaikaʻi i ke kūlana metabolic o ka poʻe maʻi, a lawelawe ma ke ʻano he koho lapaʻau hou no ka momona, kōkua i nā poʻe maʻi obese e lilo i ka kaumaha a hoʻemi i ka pilikia o nā maʻi like ʻole e pili ana i ka momona [1,2].
Hoʻemi ʻia ka pilikia o ka maʻi cardiovascular:
ʻO ka poʻe maʻi me ka maʻi diabetes type 2 e kū pinepine ana i ka piʻi nui o ka maʻi cardiovascular. Ma waho aʻe o ka hoʻohaʻahaʻa ʻana i ke kō koko a me ke kaumaha, ʻo Tirzepatid ka hopena maikaʻi i nā hōʻailona pili i ka cardiovascular, me ka hoʻohaʻahaʻa ʻana i ke koko, hoʻemi i ka hōʻiliʻili momona visceral, a me ka hoʻohaʻahaʻa ʻana i nā pae triglyceride, no laila e kōkua ai i ka hōʻemi ʻana i ka maʻi o ka maʻi cardiovascular a hoʻomaikaʻi i nā hopena cardiovascular [4].
Hiki ke mālama ʻia no ka steatohepatitis non-alcoholic (NASH):
Loaʻa iā Tirzepatid nā hopena therapeutic kūpono ma NASH. Ma ka hoʻomaikaʻi ʻana i ka naʻau o ka insulin a me ka hoʻoponopono ʻana i ka glucose a me ka metabolism lipid, hiki iā ia ke hōʻemi i ka steatosis hepatic a me ka mumū, e hāʻawi ana i kahi kuhikuhi hou no ka mālama NASH [5].
Ka hopena
Ma ke ʻano he GIP/GLP-1 ʻelua receptor agonist, ua hōʻike ʻo Tirzepatid i ka hana koʻikoʻi i ka mālama ʻana i ka maʻi diabetes a me nā maʻi metabolic. Ma ka hoʻoponopono ʻana i ka huna ʻana o ka insulin a me ka glucagon, hoʻopaneʻe i ka hoʻokaʻawale ʻana o ka ʻōpū, a me ka hoʻonui ʻana i ka māʻona, hoʻohaʻahaʻa pono ia i nā pae hemoglobin A1c a hoʻemi i ke kaumaha o ka maʻi. Hoʻohui, hoʻomaikaʻi ka lāʻau lapaʻau i nā mea pilikia cardiovascular e like me ka pae lipid a me ke kahe koko a hōʻike i ka pono i ka steatohepatitis non-alcoholic.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
Mea kākau moʻolelo ʻepekema
Hoʻopili ʻia ʻo De Block C me ke Kulanui o Antwerp a me kāna mau ʻoihana pili i Belgium, me ka Inflamed Ctr Excellence, University Hospital Antwerp (UZA a me Univ Hosp Antwerp), a me ka Infla Med Ctr Excellence. ʻO kāna noiʻi ʻana e pili ana i nā ʻano aʻoaʻo, e like me Endocrinology & Metabolism, kahi e nānā ai ʻo ia i nā hormones a me nā maʻi metabolic; Gastroenterology & Hepatology, e ʻimi ana i nā maʻi ʻai a me nā ate; General & Internal Medicine, e kamaʻilio ana i ka hōʻailona a me ka mālama ʻana i nā maʻi maʻamau o loko; Nutrition & Dietetics, e noiʻi ana i ka meaʻai a me kona hopena olakino; a me Urology & Nephrology, ke aʻo ʻana i ka pathology a me ka hana lapaʻau o nā maʻi mimi a me nā maʻi maʻi. He haumana ʻo ia me nā haʻawina nui i nā ʻoihana lapaʻau he nui. Ua helu ʻia ʻo De Block C ma ka ʻōlelo kuhikuhi [4].
